Canada approves GSK's RSV vaccine for adults aged 50 to 59
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...
Daily5h
GSK RSV vaccine approved in Canada for adults aged 50-59 at increased risk
Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...
Canada approves Moderna's RSV vaccine for adults aged 60 and older
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Canada approves Moderna's RSV vaccine for those age 60 and older, company says
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
The Pharma Letter4d
GSK’s Arexvy receives expanded approval in Canada
GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...
Reuters on MSN2d
Canada approves Moderna’s RSV vaccine, first of its kind for older adults
Health Canada has approved the vaccine, mRESVIA, for the prevention of lower respiratory tract disease in older adults, the company said.
devdiscourse5d
Global Health Update: DiaSorin Leads Diagnostic Surge While RSV and Allulose Make Waves
This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...
GlobalData on MSN5d
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59
GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...